At Roche Pharmaceuticals, we focus on finding new medicines that help patients live longer, better lives and evolve the practice of medicine.

This page lists Roche Australia’s pharmaceutical medicines. Use the search function to search by active ingredient, brand name or disease area, to find the Product Information (PI) and Consumer Medicine Information (CMI) for each product.

Actemra® (tocilizumab)

Statement for Actemra Supply Constraints

The global demand for ACTEMRA® (tocilizumab) continues to be unprecedented despite the availability of vaccines and new treatment options for COVID-19. In response, Roche has been working to increase supply globally, however uncertainty remains around the impact of emerging variants, and expected approvals of ACTEMRA for COVID-19 treatment in many countries.

Supply of ACTEMRA intravenous (IV) and ACTEMRA subcutaneous (SC) has begun to improve, although levels are yet to return to normal pre-pandemic levels. Patients who wish to resume or switch back to ACTEMRA are advised to speak to their healthcare professional.

Roche would like to provide the following update on the availability of ACTEMRA in Australia and its impact on patients:

ACTEMRA® Intravenous (IV) formulations:

Supply of ACTEMRA IV presentations is beginning to improve, although availability of the different IV strengths continues to be variable due to the unprecedented global demand. Based on modelling undertaken by the Therapeutic Goods Administration (TGA) and the Australian Rheumatology Association (ARA), clinicians are advised that ACTEMRA IV formulations can now be accessed by a broader cohort of patients.

For the latest guidance on priority conditions please refer to the ARA website for the updated joint statement on patient management prepared by the TGA, the ARA and Arthritis Australia.

ACTEMRA® Subcutaneous (SC) formulations:

The supply of ACTEMRA pre-filled syringes (PFS) and ACTEMRA pre-filled pens (ACTPen) is transitioning to normal pre-pandemic levels, and constraints have been lifted.

The Serious Scarcity Substitution Instrument (SSSI) for Actemra SC formulations expired on 30 April 2022. Please refer to the TGA website or Federal Register of Legislation for details.

Further information:
Roche recognises the concern that the ACTEMRA shortage has caused to many patients and we are continuing to work closely with the TGA, the ARA and Arthritis Australia with the goal of minimising the impact on patients in Australia. For the most up-to-date information on shortage end dates, please refer to the TGA website.

More information is available on the TGA website.

More information for rheumatologists and prescribers is available on the Australian Rheumatology Association website.

More information for patients and consumers is available on the Arthritis Australia website.

Actemra® (tocilizumab)

Availability of Actemra® (tocilizumab):

  • Pre-filled syringe for subcutaneous (SC) injection
  • Pre-filled pen for subcutaneous (SC) injection
  • Intravenous (IV) solution for infusion

Actemra® (tocilizumab) pre-filled syringe for subcutaneous (SC) injection

Patients
Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Actemra® (tocilizumab) pre-filled pen for subcutaneous (SC) injection

Patients
Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Actemra® (tocilizumab) intravenous (IV) solution for infusion

Patients
Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Alecensa® (alectinib)

Alecensa® (alectinib)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Avastin® (bevacizumab)

Avastin® (bevacizumab)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

CellCept® (mycophenolate mofetil)

CellCept® (mycophenolate mofetil)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Cotellic® (cobimetinib)

Cotellic® (cobimetinib)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Enspryng® (satralizumab)

Enspryng® (satralizumab)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Erivedge® (vismodegib)

Erivedge® (vismodegib)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Esbriet® (pirfenidone)

Esbriet® (pirfenidone)

Availability of Esbriet® (pirfenidone):

  • Tablets
  • Capsules

Esbriet® (pirfenidone) tablets

Patients
Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Esbriet® (pirfenidone) capsules

Patients
Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Evrysdi® (risdiplam)

Evrysdi® (risdiplam)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Fuzeon® (enfuvirtide)

Fuzeon® (enfuvirtide)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Gazyva® (obinutuzumab)

Gazyva® (obinutuzumab)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Hemlibra® (emicizumab)

Hemlibra® (emicizumab)

Patients
Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Herceptin® (trastuzumab) powder for IV infusion

Herceptin® (trastuzumab) powder for IV infusion

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Herceptin® SC (trastuzumab) solution for SC injection

Herceptin® SC (trastuzumab) solution for SC injection

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Invirase® (saquinavir)

Invirase® (saquinavir)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals

Product Information (PI)

Kadcyla® (trastuzumab emtansine)

Kadcyla® (trastuzumab emtansine)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

MabThera® (rituximab) solution for IV infusion

MabThera® (rituximab) solution for IV infusion

Patients

NHL/CLL Consumer Medicine Information (CMI)

RA/GPA/MPA Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

MabThera® SC (rituximab) solution for SC injection

MabThera® SC (rituximab) solution for SC injection

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Madopar® (levodopa and benserazide)

Madopar® (levodopa and benserazide)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Mircera® (methoxy polyethylene glycolepoetin beta)

Mircera® (methoxy polyethylene glycolepoetin beta)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals 
Product Information (PI)

NeoRecormon® (epoetin beta)

NeoRecormon® (epoetin beta)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Ocrevus® (ocrelizumab)

Ocrevus® (ocrelizumab)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Pegasys® (peginterferon alfa-2a)

Pegasys® (peginterferon alfa-2a)

In May 2022, Roche transferred the sponsorship and management of supply, customer support, medical information, regulatory services, sales and marketing of Pegasys to Echo Therapeutics Pty Ltd in Australia. The current Consumer Medicine Information (CMI) and Product Information (PI) for Pegasys are available from the Therapeutic Goods Administration (TGA) website at: https://www.ebs.tga.gov.au/

Perjeta® (pertuzumab)

Perjeta® (pertuzumab)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Polivy® (polatuzumab vedotin)

Polivy® (polatuzumab vedotin)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Pulmozyme® (dornase alfa)

Pulmozyme® (dornase alfa)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Rivotril® (clonazepam)

Rivotril® (clonazepam)

In August 2021, Roche transferred the sponsorship and management of supply, customer support, medical information, regulatory services, sales and marketing of Rivotril (clonazepam) to Pharmaco Australia Ltd within Australia. The current Consumer Medicine Information (CMI) and Product Information (PI) for Valium are available from the Therapeutic Goods Administration (TGA) website at: https://www.ebs.tga.gov.au/

Roaccutane® (isotretinoin)

Roaccutane® (isotretinoin)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Rocaltrol® (calcitriol)

Rocaltrol® (calcitriol)

Please be advised that Roche has transitioned responsibility of Rocaltrol to Atnahs. Please contact Atnahs for the current Product Information (PI) and Consumer Medicine Information (CMI).

Ronapreve® (casirivimab and imdevimab)

Ronapreve® (casirivimab and imdevimab)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Rozlytrek® (entrectinib)

Rozlytrek® (entrectinib)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals 
Product Information (PI)

Tamiflu® (oseltamivir) capsules

Tamiflu® (oseltamivir) capsules

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Tamiflu® (oseltamivir) suspension

Tamiflu® (oseltamivir) suspension availability - 26 June 2019

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Tarceva® (erlotinib)

Tarceva® (erlotinib)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Tecentriq® (atezolizumab)

Tecentriq® (atezolizumab)

Roche update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer - IMpassion131 results.

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Valcyte® (valganciclovir) powder for oral solution

Valcyte® (valganciclovir) powder for oral solution

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Valcyte® (valganciclovir) tablets

Valcyte® (valganciclovir) tablets

Patients
Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Valium® (diazepam)

Valium® (diazepam)

In August 2021, Roche transferred the sponsorship and management of supply, customer support, medical information, regulatory services, sales and marketing of Valium (diazepam) to Atnahs Pharma Australia Pty Ltd within Australia. The current Consumer Medicine Information (CMI) and Product Information (PI) for Valium are available from the Therapeutic Goods Administration (TGA) website at: https://www.ebs.tga.gov.au/

Xofluza® (Baloxavir marboxil)

Xofluza® (baloxavir marboxil)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)

Zelboraf® (vemurafenib)

Zelboraf® (vemurafenib)

Patients

Consumer Medicine Information (CMI)

Healthcare Professionals
Product Information (PI)